Form D · Private Equity Fund

MW XO Health Innovations Fund, LP

Camana Bay, Grand Cayman, E9 · CIK 0001849328

Offering snapshot reported Mar 8, 2022 · SEC filing

Reported sold: $150M
Investors reported: 1
Minimum accepted: $0
First sale: Apr 7, 2021

What changed?

Latest filing versus its linked predecessor, where available.

Reported investors0 → 1

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 8, 2022	Amendment	$150,000,000	No comparison	1	SEC filing
Mar 11, 2021	Initial	Yet to sell	No comparison	0	SEC filing
Mar 8, 2021	Initial	Yet to sell	No comparison	0	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06c, 3C, 3C.7
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-391817

Source: Form D, filed Mar 8, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

Each card uses that adviser's latest imported filing. Filing dates can differ; these disclosures do not confirm a current relationship.

Matched by reported Form D file number

MW XO HEALTH INNOVATIONS FUND, LP

Investment adviser: MARSHALL WACE NORTH AMERICA L.P.

Gross asset value: $300M
Beneficial owners: 44
ADV minimum commitment: $20M

Reported in Form ADV on Jul 30, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator CITCO FUND SERVICES (IRELAND) LTD DUBLIN, Ireland Investor statements: Yes (provided to all investors) Related to adviser: No Other funds reporting this name →

Auditor ERNST & YOUNG DUBLIN, Ireland Other funds reporting this name →

Custodian CITCO BANK NEDERLAND N.V. DUBLIN BRANCH DUBLIN, Ireland Related to adviser: No Other funds reporting this name →

Prime broker CITIGROUP GLOBAL MARKETS INC. NEW YORK, New York, United States Other funds reporting this name →

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: No

ERNST & YOUNG
PCAOB 1411

Fund asset history · 5 annual observations

Scroll to see all columns →

Fiscal year	Gross assets	Beneficial owners	ADV filed
2022	$97,757,524	42	May 25, 2022
2023	$119,012,778	1,594	May 30, 2023
2024	$221,676,352	44	May 30, 2024
2025	$230,861,194	44	May 29, 2025
2026	$300,188,334	44	May 29, 2026

Filing source

Form ADV 2122955 · Jul 30, 2026 · Schedule D 7.B.(1), fund 805-5481089293

Reported by MARSHALL WACE NORTH AMERICA L.P. (CRD 135902).

Other-Than Anual Amendment For Registered Adviser.

Official IAPD profile (latest public filing). Historical values on this page come from the SEC/IAPD filing archive; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Alaina Danley	Director
Scott P. Lennon	Director
Marshall Wace Asia Limited	Promoter
Marshall Wace Llp	Promoter
Marshall Wace North America L.P.	Promoter
Claire Musgrave	Director
Mw Xo Health Innovations Fund Gp Ltd	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

C/O Mw Xo Innovations Fund Gp Ltd Waystone, Suite 5 B201, One Nexus Way
Camana Bay, Grand Cayman, E9, KY1-1103